Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
出版年份 2013 全文链接
标题
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
作者
关键词
-
出版物
Blood Cancer Journal
Volume 3, Issue 6, Pages e120-e120
出版商
Springer Nature
发表日期
2013-06-07
DOI
10.1038/bcj.2013.18
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop
- (2014) E. Menoret et al. JOURNAL OF IMMUNOLOGY
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells
- (2012) David Chiron et al. BLOOD CELLS MOLECULES AND DISEASES
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients
- (2011) David Chiron et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
- (2011) B Paiva et al. LEUKEMIA
- Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival
- (2010) T. Steinbrunn et al. BLOOD
- Novel therapeutic targets for multiple myeloma
- (2010) Anuj Mahindra et al. Future Oncology
- CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features
- (2010) M. Schmidt-Hieber et al. HAEMATOLOGICA
- A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
- (2010) J. Moreaux et al. HAEMATOLOGICA
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
- (2009) Anne Catherine Sprynski et al. BLOOD
- A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
- (2009) G Descamps et al. BRITISH JOURNAL OF CANCER
- Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy
- (2009) K. S.M. Smalley et al. CANCER RESEARCH
- Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
- (2009) N. Chapuis et al. HAEMATOLOGICA
- Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity
- (2008) J. C. Montero et al. HAEMATOLOGICA
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
- (2007) Régis Bataille et al. LEUKEMIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started